HD10 for Early Stages

Conditions

Hodgkin´s Lymphoma

Keywords

Hodgkin´s lymphoma, early stages

Brief summary

This study is designed to find the optimum radiation dose and number of cycles for an ABVD chemotherapy combined with an involved field irradiation. It is to be tested whether the reduction from 4 to 2 cycles of ABVD and/or the reduction of the radiation dose from 30 to 20 Gy is feasible without a loss of efficacy.

Bröckelmann PJ, Müller H, Casasnovas O, Hutchings M, von Tresckow B, Jürgens M, McCall SJ, Morschhauser F, Fuchs M, Borchmann P, Moskowitz CH, Engert A.

2017-06-0158 citations

10.1093/annonc/mdx072

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Boris Böll, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Felicitas Hitz et al. (15 authors)

Blood2016-02-02112 citations

10.1182/blood-2015-11-681064

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.

Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz MK, Borchmann P, Connors JM, Markova J, Crump M, Lohri A, Winter JN, Dörken B, Pearcey RG, Diehl V, Horning SJ, Eich HT, Engert A, Meyer RM, Conducted by the NCIC Clinical Trials Group (Canada) and German Hodgkin Study Group (GHSG).

2013-10-1131 citations

10.1093/annonc/mdt389

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V.

2010-08-01583 citations

10.1056/nejmoa1000067

Interventions

DRUGAdriamycin

DRUGBleomycin

DRUGVinblastine

DRUGDTIC

RADIATION30 Gy IF-RT

RADIATION20 Gy IF-RT

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

16 Years to 75 Years

Healthy volunteers

No

Inclusion criteria

* Hodgkin´s lymphoma (histologically proven) * CS (PS) IA, IB, IIA,IIB without any of the following risk factors: 1. bulky mediastinal mass (\> 1/3 maximum transverse thorax diameter) 2. extranodal involvement 3. ESR \> 50 (A), \> 30 (B-symptoms) 4. 3 or more lymph node areas involved * written informaed consent

Exclusion criteria

* Leukocytes \<3000/microl * Platelets \<100000/microl * Hodgkin´s Disease as composite lymphoma * Activity index (WHO) \< grade 2

Design outcomes

Primary

Measure	Time frame
Progression free survival (PFS)	5 years

Outcome results

None listed